Pure Global
NCT06102486

MCI Speech in Noise

Speech Perception in Noise as an Improved Marker for Neurocognitive Dysfunction
Dartmouth-Hitchcock Medical Center·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Mild Cognitive Impairment
Study type
Observational
Sponsor & location
Primary sponsor
Dartmouth-Hitchcock Medical Center
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Jun 01, 2025
Enrollment
70 participants
Primary outcome

Hearing-in-Noise Test Performance,Triple Digit in Noise Test Performance,Size of auditory neural response in background noise,Timing of auditory neural response in background noise

Summary

The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment)
 and healthy comparison subjects differ with respect to their ability to hear soft sounds and
 how their brain understands and processes sound. The investigators are also evaluating,
 within those with MCI, whether the hearing tests are associated with neurocognitive
 functioning. The investigators are interested in learning whether changes in cognition in
 those with MCI can be detected using tests of how the brain processes sound. The
 investigators hypothesize that participants with MCI will score worse on both hearing tests
 and neurocognitive tests than participants without MCI. Participants are asked to complete
 multiple types of hearing tests, take a series of neurocognitive tests, and complete a few
 questionnaires.

ICD-10 classifications
Mild cognitive disorderAlzheimer diseaseDementia in other specified diseases classified elsewhereDementia in other diseases classified elsewhereDementia in Alzheimer disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06102486
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06102486 through Pure Global AI's free database. This phase not specified trial is sponsored by Dartmouth-Hitchcock Medical Center and is currently Not yet recruiting. The study focuses on Mild Cognitive Impairment. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.